All News

Are the GLP-1 Agonists "Forever Drugs?" It's an Open Question, According to Jonathan Bonnet, MD, MPH
August 08, 2025

The obesity and lifestyle medicine specialist says while research on the question continues, a focus on optimizing nutritional health during treatment is essential.

The TikTok Doc Is In: But Will Your Patient Trust the Diagnosis?
August 08, 2025

Health information permeates social media platforms exposing Americans to advice, even when they don't want it. The good news? Not many trust it!

How Physicians Can Strengthen Vaccine Confidence During National Immunization Awareness Month
August 08, 2025

Board-certified family physician Sarah Sams, MD, urges physicians to actively engage their communities to build vaccine confidence and combat misinformation.

Excess Intake of Ultraprocessed Foods is Tied to Higher Cardiometabolic Risk, AHA Advisory Panel Says
August 08, 2025

The Advisory Panel laid out 4 priority actions for clinicians, policy makers, and industry.

Novel Plasma Assays That Selectively Detect Tau Characteristics Will Refine Clinical Study of Alzheimer Disease
August 08, 2025

The 2 new plasma assays to enhance Alzheimer’s disease research will support disease staging, predicting disease progression, and monitoring treatment outcome.

FDA Approves Finerenone for Treatment of Heart Failure With LVEF ≥40%: Daily Dose
August 08, 2025

Your daily dose of the clinical news you may have missed.

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression
August 07, 2025

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

GLP-1 Medications Need a Permanent Place in Primary Care, Says Obesity Medicine Specialist
August 07, 2025

Jonathan Bonnet, MD, MPH, encourages primary care clinicians to embrace GLP-1 therapy where appropriate to stem multiple risk factors for downstream chronic diseases.

Use of Weight-Loss Drugs Increased Among US Adolescents After AAP Guideline Release
August 07, 2025

New data shows pediatric pharmacotherapy prescribing rose but remained infrequent, while nutrition counseling rates changed minimally.

Lilly's Oral GLP-1 Agonist Orforglipron Linked to Weight Reduction of 12.4% in Pivotal Phase 3 Trial
August 07, 2025

The investigational daily oral GLP-1 RA met the primary endpoint for body weight reduction at 72 weeks and also improved a range of cardiovascular risk factors.